News and CommentScience and Commerce

Disclosing Data Can Get You in Trouble

See allHide authors and affiliations

Science  02 May 1997:
Vol. 276, Issue 5313, pp. 671-672
DOI: 10.1126/science.276.5313.671b

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

On 10 April, the U.S. Securities and Exchange Commission (SEC) filed insider-dealing charges against two clinical researchers, accusing them of illegally disclosing early, negative results in a trial of a hepatitis-B drug (thymosin alpha 1), allowing friends and relatives to beat the market by selling off stocks.